Latest Breaking News On - Christine fanelle - Page 1 : vimarsana.com

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers -January 30, 2024 at 08:06 am EST

Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancersROCKVILLE, Md. and ST. LOUIS, Jan. 30, 2024 --...

Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China's National Reimbursement Drug List -December 13, 2023 at 08:54 am EST

BOSTON, Dec. 13, 2023 -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for life-threatening diseases and other...

Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting

Wugen to Present New Clinical Data for WU-CART-007 and

-- Oral Presentation Highlights Latest Clinical Findings from First Global, In-Human Phase 1/2 Dose-Escalation Study of Anti-CD7 Off-the-Shelf Allogeneic...

Wugen to Present New Clinical Data for WU-CART-007 and Preclinical Data for WU-NK-101, Two ...

-- Oral Presentation Highlights Latest Clinical Findings from First Global, In-Human Phase 1/2 Dose-Escalation Study of Anti-CD7 Off-the-Shelf Allogeneic CAR-T Cell Therapy, WU-CART-007, in Hard-to-Treat T-ALL/LBL Patients

Wugen to Present New Clinical Data for WU-CART-007 and Preclinical Data for WU-NK-101, Two Investigational Allogeneic Cell Therapies for Challenging Hematologic Cancers, at American Society of Hematology Annual Meeting & Exposition

Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter

Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter

Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million

16.03.2023 - - NUZYRA (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the Prior Year - Continued Progress on the Rare Disease Nontuberculous Mycobacteria (NTM) & BARDA Project BioShield Anthrax ...

Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16

BOSTON, March 08, 2023 -- Paratek Pharmaceuticals, Inc. today announced that the company will host a conference call and live audio webcast on Thursday, March 16, 2023 at 8:30 a.m. EST to provide... | March 8, 2023